Form 4: Palisade Bio Director Granted 1.5M Restricted Stock Units

Palisade Bio director Donald Allen Williams was granted 1,538,700 Restricted Stock Units, vesting over three years.

Summary

• Donald Allen Williams, a Director of PALISADE BIO, INC. (PALI), was granted 1,538,700 Restricted Stock Units (RSUs).
• The transaction date for this grant was October 6, 2025.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• RSUs may be settled in cash if the Issuer has insufficient shares reserved under its 2021 Equity Incentive Plan.
• The RSUs are subject to a service-based vesting requirement and will vest in three equal annual installments.
• Vesting will occur on the earlier of the next annual meeting of stockholders or the anniversary of October 6, 2025, contingent on continuous service.

Sentiment

Score: 7

Explanation: The filing reports a routine equity compensation grant to a director, which is generally viewed as a positive for aligning management interests with shareholders. It does not contain any negative surprises or significant new risks beyond the standard terms of such grants.

Positives

• The grant of Restricted Stock Units aligns the director's interests with those of shareholders, incentivizing long-term performance.
• Equity compensation is a standard practice for retaining and motivating key personnel, including directors.

Risks

• The RSUs may be settled in cash instead of common stock if Palisade Bio has insufficient shares reserved under its 2021 Equity Incentive Plan, which could impact the director's direct equity ownership.
• Vesting is contingent on the reporting person's continuous service with the Issuer, meaning the RSUs could be forfeited if service ceases before vesting dates.

Future Outlook

The granted Restricted Stock Units are subject to a service-based vesting requirement, with vesting occurring in three equal annual installments starting from October 6, 2025, or the date of the next annual meeting of stockholders, whichever is earlier, provided continuous service is maintained.

Industry Context

The grant of Restricted Stock Units to a director is a common form of equity compensation in the biotechnology and broader corporate sectors. It serves to align the interests of the director with long-term shareholder value and is a standard component of executive and board remuneration packages.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) for director compensation is a widely accepted practice across various industries, including biotech, aligning with global benchmarks for corporate governance and incentive structures.
• The three-year vesting schedule is typical for such equity grants, providing a long-term incentive for continued service and performance, comparable to practices at companies like Amgen or Gilead Sciences for their non-executive directors.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon RSU vesting and conversion to common stock, but also improved alignment of director interests with long-term company performance.
• Employees: No direct impact mentioned, but the 2021 Equity Incentive Plan is referenced, which may also cover other employees.

Next Steps

• The Restricted Stock Units will vest in three equal annual installments, contingent on the director's continuous service with the Issuer.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a director. While it aligns the director's interests with shareholders, it does not present new fundamental information or significant changes to the company's financial health or strategic outlook that would warrant a change in investment recommendation. It is a standard operational disclosure.

Keywords

PALI, Palisade Bio, Form 4, Restricted Stock Units, RSU, insider transaction, director compensation, equity incentive plan